EVestG™ technology is a breakthrough in the diagnosis and treatment of psychiatric and neurological disorders.

EVestG™ Biomarkers of Brain Function support a Clinician make a faster and more accurate objective diagnosis of psychiatric or neurological disorders within minutes of testing. With EVestG™, a greater than 80% accurate diagnosis will be possible at the first visit to the clinician’s office.

The product of nearly a decade of research and development, EVestG™ represents potential for an historic change in the diagnosis and management of global mental and brain health. 

Existing diagnostic methodology for psychiatric and neurological disorders is subjective and lacks the accuracy and consistency required for the management of such a massive, global health issue. 

This absence of effective diagnostic technology causes delays in early appropriate intervention that contribute significantly to the projected current $16 Trillion per year to be spent by 2030 in managing the direct and indirect costs to the community and medical burden of these disorders.”

NeuralDx’s EVestG™ technology can discriminate between different psychiatric and neurological disorders with an objective test that takes no longer than one hour to administer and interpret.